Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 312

1.

Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation.

Syed GH, Tang H, Khan M, Hassanein T, Liu J, Siddiqui A.

J Virol. 2014 Mar;88(5):2519-29. doi: 10.1128/JVI.02727-13. Epub 2013 Dec 18.

2.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

3.

PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.

Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RD, Bassendine MF.

J Hepatol. 2015 Apr;62(4):763-70. doi: 10.1016/j.jhep.2014.11.016. Epub 2014 Nov 21.

PMID:
25463543
4.

Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.

Duan Y, Chen Y, Hu W, Li X, Yang X, Zhou X, Yin Z, Kong D, Yao Z, Hajjar DP, Liu L, Liu Q, Han J.

J Biol Chem. 2012 Jul 6;287(28):23667-77. doi: 10.1074/jbc.M112.350181. Epub 2012 May 16.

5.

Effect of Porphyromonas gingivalis infection on post-transcriptional regulation of the low-density lipoprotein receptor in mice.

Miyazawa H, Tabeta K, Miyauchi S, Aoki-Nonaka Y, Domon H, Honda T, Nakajima T, Yamazaki K.

Lipids Health Dis. 2012 Sep 19;11:121. doi: 10.1186/1476-511X-11-121.

6.

β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.

Starr AE, Lemieux V, Noad J, Moore JI, Dewpura T, Raymond A, Chrétien M, Figeys D, Mayne J.

FEBS J. 2015 Jul;282(14):2682-96. doi: 10.1111/febs.13309. Epub 2015 May 18.

7.

Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.

Le QT, Blanchet M, Seidah NG, Labonté P.

J Biol Chem. 2015 Sep 18;290(38):23385-400. doi: 10.1074/jbc.M115.642991. Epub 2015 Jul 20.

8.

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.

Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.

Circulation. 2014 Jul 29;130(5):431-41. doi: 10.1161/CIRCULATIONAHA.113.006720. Epub 2014 May 23. Erratum in: Circulation. 2015 May 5;131(18):e429.

9.

Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A.

Li Z, Liu Q.

J Gen Virol. 2018 Jan;99(1):44-61. doi: 10.1099/jgv.0.000987. Epub 2017 Dec 13.

PMID:
29235977
10.

MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.

Yan H, Ma YL, Gui YZ, Wang SM, Wang XB, Gao F, Wang YP.

Acta Pharmacol Sin. 2014 Aug;35(8):994-1004. doi: 10.1038/aps.2014.52. Epub 2014 Jul 21.

11.

Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.

Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1171-8. doi: 10.1161/ATVBAHA.113.302670. Epub 2014 Mar 27.

PMID:
24675665
12.

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.

Ramanathan A, Gusarova V, Stahl N, Gurnett-Bander A, Kyratsous CA.

PLoS One. 2016 Apr 26;11(4):e0154498. doi: 10.1371/journal.pone.0154498. eCollection 2016.

13.

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.

Lagace TA.

Curr Opin Lipidol. 2014 Oct;25(5):387-93. doi: 10.1097/MOL.0000000000000114. Review.

14.

Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.

Yang JH, Bang MA, Jang CH, Jo GH, Jung SK, Ki SH.

J Nutr Biochem. 2015 Nov;26(11):1393-400. doi: 10.1016/j.jnutbio.2015.07.009. Epub 2015 Jul 30.

PMID:
26320675
15.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG.

PLoS One. 2013 May 13;8(5):e64145. doi: 10.1371/journal.pone.0064145. Print 2013.

16.

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.

Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, Corsini A, Catapano AL.

Atherosclerosis. 2012 Feb;220(2):381-6. doi: 10.1016/j.atherosclerosis.2011.11.026. Epub 2011 Nov 25.

PMID:
22176652
17.

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Maxwell KN, Breslow JL.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5. Epub 2004 Apr 26.

18.

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.

Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, Bottomley MJ, Ruggeri L, Cummings RT, Cubbon RM, Santoro JC, Ehrhardt A, Lewis D, Fisher TS, Ha S, Njimoluh L, Wood DD, Hammond HA, Wisniewski D, Volpari C, Noto A, Lo Surdo P, Hubbard B, Carfí A, Sitlani A.

J Biol Chem. 2010 Apr 23;285(17):12882-91. doi: 10.1074/jbc.M110.113035. Epub 2010 Feb 19.

19.

Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.

Tavori H, Fan D, Blakemore JL, Yancey PG, Ding L, Linton MF, Fazio S.

Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20.

20.

Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Butkinaree C, Canuel M, Essalmani R, Poirier S, Benjannet S, Asselin MC, Roubtsova A, Hamelin J, Marcinkiewicz J, Chamberland A, Guillemot J, Mayer G, Sisodia SS, Jacob Y, Prat A, Seidah NG.

J Biol Chem. 2015 Jul 24;290(30):18609-20. doi: 10.1074/jbc.M115.647180. Epub 2015 Jun 17.

Supplemental Content

Support Center